2-Arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors

British Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2010, Pages 180-188

  Keown, Oliver P ^a   Winterburn, Timothy J ^a   Wainwright, Cherry L ^b   MacRury, Sandra M ^a   Neilson, Ilene ^a   Barrett, Fiona ^a   Leslie, Stephen J ^a,c   Megson, Ian L ^a  

^a UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

^c RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

2 AG; AM251; antithrombotic; endocannabinoid system; platelets; rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACETYLSALICYLIC ACID; ACYLGLYCEROL LIPASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; FATTY ACID AMIDASE; PROSTAGLANDIN SYNTHASE; TETRAHYDROCANNABINOL;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADOLESCENT; ADULT; AGED; ARACHIDONIC ACIDS; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; RECEPTORS, CANNABINOID; YOUNG ADULT;

EID: 77954485198     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03697.x     Document Type: Article

References (32)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 346 : 561 564.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993 365 : 61 5.
3. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007 14 : 1347 1356.
4. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008 20 (Suppl. 1 1 9.
5. 2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008 118 : 18 35.
6. Mackie K. Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol 2008 286 : S60 5.
7. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 2004 99 : 1127 1130.
8. Docagne F, Mestre L, Loria F, Hernangomez M, Correa F, Guaza C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets 2008 12 : 185 195.
9. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005 7 : E625 54.
10. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 2005 168 : 117 145.
11. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005 8 : 585 589.
12. 1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003 41 : 657 664.
13. 1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999 276 : H2085 93.
14. Levy R, Schurr A, Nathan I, Dvilanski A, Livne A. Impairment of ADP-induced platelet aggregation by hashish components. Thromb Haemost 1976 36 : 634 640.
15. Maccarrone M, Bari M, Menichelli A, Del Principe D, Agro AF. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 1999 447 : 277 282.
16. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001 268 : 819 825.
17. Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 1989 41 : 705 709.
18. Braud S, Bon C, Touqui L, Mounier C. Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 2000 471 : 12 6.
19. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003 112 : 423 431.
20. Williams CM, Kirkham TC. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002 71 : 333 340.
21. Scheen AJ, Van Gaal LG, Despres JP, Pi-Sunyer X, Golay A, Hanotin C. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. Rev Med Suisse 2006 2 : 1916 1923.
22. Van Gaal LF, Michiels JJ. Obesity, health issues, and cardiovascular disease. Semin Vasc Med 2005 5 : 1 2.
23. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005 76 : 1307 1324.
24. Golanski J, Pietrucha T, Baj Z, Greger J, Watala C. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood - various anticoagulants are not equal. Thromb Res 1996 83 : 199 216.
25. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets 2000 11 : 320 324.
26. Serebruany V, Mckenzie M, Meister A, Fuzaylov S, Gurbel P, Atar D, Gattis W, O'Connor C. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT trial). Eur J Heart Fail 2002 4 : 461 467.
27. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005 435 : 1108 1112.
28. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005 168 : 1 51.
29. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007 152 : 984 986.
30. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 1992 261 : 114 122.
31. Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in zucker rats. Br J Pharmacol 2008 154 : 1047 1054.
32. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance. J Am Coll Cardiol 2009 53 : 667 677.